These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Increased Risk of Venous Thromboembolic Events With Corticosteroid Versus Biologic Therapy for Inflammatory Bowel Disease. Murthy SK; Nguyen GC Clin Gastroenterol Hepatol; 2016 Jan; 14(1):166-7. PubMed ID: 25929541 [No Abstract] [Full Text] [Related]
9. Safety issues with biological therapies for inflammatory bowel disease. Van Assche G; Vermeire S; Rutgeerts P Curr Opin Gastroenterol; 2006 Jul; 22(4):370-6. PubMed ID: 16760752 [TBL] [Abstract][Full Text] [Related]
10. Inflammatory bowel disease therapies for the 1990s: scientific basis and clinical experience. Report of a symposium. December 8, 1989, New York City. Mt Sinai J Med; 1990 Oct; 57(5):271-332. PubMed ID: 1982891 [No Abstract] [Full Text] [Related]
12. Proceedings of the First International Symposium on Pediatric Inflammatory Bowel Disease. September 16-18, 2003. Irvington, Virginia, U.S.A. J Pediatr Gastroenterol Nutr; 2005 Apr; 40 Suppl 1():S2-3. PubMed ID: 15805833 [No Abstract] [Full Text] [Related]
13. The risks and benefits of early immunosuppression and biological therapy. Sands BE Dig Dis; 2012; 30 Suppl 3():100-6. PubMed ID: 23295699 [TBL] [Abstract][Full Text] [Related]
14. Risks and benefits of biologic therapy for inflammatory bowel diseases. D'Haens G Gut; 2007 May; 56(5):725-32. PubMed ID: 17440187 [No Abstract] [Full Text] [Related]
15. [Current concepts about the treatment of inflammatory bowel disease, biological therapy]. Bosques-Padilla FJ; Galindo-Marines SL; Yamamoto-Farusho JK Rev Gastroenterol Mex; 2008; 73(4):217-30. PubMed ID: 19666271 [TBL] [Abstract][Full Text] [Related]
16. Loss of response to biologics versus increased risk of lymphoma in children with inflammatory bowel disease: the clinician's conundrum. Bern EM; Bousvaros A Expert Rev Clin Immunol; 2013 Feb; 9(2):117-27. PubMed ID: 23390943 [TBL] [Abstract][Full Text] [Related]
17. Vitamin D deficiency in patients with either rheumatic diseases or inflammatory bowel diseases on biologic therapy. Bruzzese V; Zullo A; Picchianti Diamanti A; Ridola L; Lorenzetti R; Marrese C; Scolieri P; De Francesco V; Hassan C; Migliore A; Laganà B Intern Emerg Med; 2016 Sep; 11(6):803-7. PubMed ID: 26939587 [TBL] [Abstract][Full Text] [Related]
18. What are the guidelines for using biologics in pediatric patients? de Zoeten E; Mamula P Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S259-61. PubMed ID: 18816770 [No Abstract] [Full Text] [Related]
19. "New drugs: kids come first": children should be included in trials of new biological treatments. Cucchiara S; Morley-Fletcher A Inflamm Bowel Dis; 2007 Sep; 13(9):1165-9; discussion 1176-7. PubMed ID: 17455208 [TBL] [Abstract][Full Text] [Related]
20. New drugs: kids come first; con: first adults, then children. Murphy MS Inflamm Bowel Dis; 2007 Sep; 13(9):1170-5; discussion 1176-7. PubMed ID: 17538986 [No Abstract] [Full Text] [Related] [Next] [New Search]